CGA
CRDF icon

Crescent Grove Advisors’s Cardiff Oncology CRDF Stock Holding History

Crescent Grove Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,194
Closed -$26K – 147
2017
Q4 		$26K Buy
1,194
+222
+23% +$9.83K 0.01% 145
2017
Q3 		$51K Buy
972
+444
+84% +$27.7K 0.01% 138
2017
Q2 		$48K Buy
+528
New +$34K 0.01% 144

Other funds holding CRDF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Elkhorn Partners Omaha, Nebraska $117M AUM 28.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Crescent Grove Advisors's CRDF Position: Q1 2018 in Review

Crescent Grove Advisors sold out of Cardiff Oncology (CRDF) in Q1 2018, closing a stake of 1,194 shares — an estimated $26K sold.

Crescent Grove Advisors first reported a position in CRDF in Q2 2017 and held it in 3 quarters. The position peaked at $51K in Q3 2017. 37 funds tracked by Wall St. Rank hold CRDF as of Q1 2018.

  • Crescent Grove Advisors reported no remaining Cardiff Oncology position as of Q1 2018 after selling out during the quarter.
  • Crescent Grove Advisors sold 1,194 Cardiff Oncology shares in Q1 2018, an estimated $26K.
  • Crescent Grove Advisors first reported a position in Cardiff Oncology in Q2 2017 and held it in 3 quarters.
  • Crescent Grove Advisors's Cardiff Oncology position peaked at $51K in Q3 2017.
  • 37 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2018.

Based on Crescent Grove Advisors's 13F filing for Q1 2018, filed 3 May 2018.